Chimerix (CMRX) Competitors

Chimerix has higher earnings, but lower revenue than Alumis. Chimerix is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Alumis has a consensus target price of $38.60, indicating a potential upside of 49.12%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Chimerix.

Chimerix has a net margin of 0.00% compared to Alumis' net margin of -1,011.75%. Chimerix's return on equity of -50.78% beat Alumis' return on equity.

Chimerix has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, Alumis has a beta of -0.31, meaning that its stock price is 131% less volatile than the S&P 500.

45.4% of Chimerix shares are owned by institutional investors. 13.1% of Chimerix shares are owned by company insiders. Comparatively, 40.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alumis had 1 more articles in the media than Chimerix. MarketBeat recorded 1 mentions for Alumis and 0 mentions for Chimerix. Chimerix's average media sentiment score of 0.00 equaled Alumis'average media sentiment score.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 13.1% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Chimerix has lower revenue, but higher earnings than Arcus Biosciences. Chimerix is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Arcus Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.

Chimerix has a net margin of 0.00% compared to Arcus Biosciences' net margin of -142.91%. Chimerix's return on equity of -50.78% beat Arcus Biosciences' return on equity.

Arcus Biosciences presently has a consensus target price of $32.44, suggesting a potential upside of 31.37%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than Chimerix.

In the previous week, Arcus Biosciences had 10 more articles in the media than Chimerix. MarketBeat recorded 10 mentions for Arcus Biosciences and 0 mentions for Chimerix. Chimerix's average media sentiment score of 0.00 beat Arcus Biosciences' score of -0.06 indicating that Chimerix is being referred to more favorably in the news media.

Beam Therapeutics has a consensus target price of $49.36, suggesting a potential upside of 69.26%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Chimerix.

Chimerix has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.

45.4% of Chimerix shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 13.1% of Chimerix shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Chimerix. Beam Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Chimerix has a net margin of 0.00% compared to Beam Therapeutics' net margin of -57.24%. Beam Therapeutics' return on equity of -30.65% beat Chimerix's return on equity.

In the previous week, Beam Therapeutics had 5 more articles in the media than Chimerix. MarketBeat recorded 5 mentions for Beam Therapeutics and 0 mentions for Chimerix. Beam Therapeutics' average media sentiment score of 0.76 beat Chimerix's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Gemini Therapeutics has lower revenue, but higher earnings than Chimerix. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

45.4% of Chimerix shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 13.1% of Chimerix shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Gemini Therapeutics had 1 more articles in the media than Chimerix. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Chimerix. Chimerix's average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Chimerix has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Gemini Therapeutics' return on equity of -38.78% beat Chimerix's return on equity.